PsyIMPACT is MQ’s flagship research initiative to support improvements in psychological treatments.
The PsyIMPACT programme was developed to fill crucial gaps in mental healthcare. Through this programme we fund research to develop and test innovative, theory-driven psychological interventions. The programme is overseen by a committee of leading scientists in the field of psychological research.
The PsyIMPACT programme
In the first major investment of the programme, MQ has awarded £1.5 million to four new research projects trialing innovative new ways to improve the effectiveness and accessibility of psychological therapies.
The 2014 PsyIMPACT projects are:
- Developing more accessible evidence-based psychological treatments for worry and rumination in anxiety and depression - A team at King's College London, is exploring new psychological treatments for ‘worry and rumination’, a dominant symptom of depression and anxiety disorder across all cultures. This aims to address the fact that people with high levels of worry and rumination often do not get better through traditional CBT therapy.
- Attention Control Training for Infants at risk of ADHD - The first trial of a computer-based preventative intervention for 10-month old infants at risk of ADHD. The research team at Birkbeck, University of London hope that this novel early intervention approach will provide a much-needed and targeted approach to attention and behaviors thought to be hallmarks of ADHD.
- Effectiveness and cost-effectiveness of an self-directed internet-based therapy for social anxiety symptoms - A public health approach, harnessing the internet to tackle social anxiety symptoms in the general population, at the University of Oxford.
- The Personalized Advantage Index (PAI) – Investigators at the University of Pennsylvania developing a new analytic tool that mental health professionals can use to predict which psychological treatments are likely to be the most effective for each patient.
Interested in applying for our Fellows programme?